Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging

NEXT STORY
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer
PREV STORY
National Experts in Autoimmunity Tapped to Serve on Exagen’s Scientific Advisory Board
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biopharma Leaders Unite to Stand with Science

author_avatar
NASDAQ Market News

Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers

CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers ...

author_avatar
NASDAQ Market News

Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)

Investigational therapy uses individual patient’s own stem cells to potentially regenerate and repair damaged ...

author_avatar
NASDAQ Market News